Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTRIDGE: BI 765128 in Diabetic Macular Ischemia
NCT04919499Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of BI 765128 in Macular Ischemia (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Subjects With Ocular Dose Limiting Events (DLEs) From Drug Administration Until Day 8 and Number of Subjects With Drug Related Adverse Events (AEs) From Drug Administration Until End of Study at Day 141. Started Jul 2021; status: completed.
02
Drugs
BI 765128
03
Conditions
Macular Ischemia
Beyond the preview
Go deeper on NCT04919499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919499.